We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
+23.47%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.49B
AUM Growth
+$497M
Cap. Flow
+$299M
Cap. Flow %
8.55%
Top 10 Hldgs %
38.36%
Holding
80
New
20
Increased
14
Reduced
16
Closed
14

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$161M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$139M
3
APLS
Apellis Pharmaceuticals
APLS
+$63.7M
4
DYN icon
Dyne Therapeutics
DYN
+$57.8M
5
NTLA icon
Intellia Therapeutics
NTLA
+$54.5M

Top Sells

Rank Stock Value
1
AMAM
Ambrx Biopharma Inc
AMAM
+$52.8M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$48.2M
3
RAPT
RAPT Therapeutics
RAPT
+$44.6M
4
ACLX
Arcellx
ACLX
+$40.2M
5
ANAB icon
AnaptysBio
ANAB
+$35.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
$171M 4.91%
3,479,853
-583,823
-14% -$27M
AMGN icon
2
Amgen
AMGN
$210B
$156M 4.48%
+550,000
New +$161M
APGE icon
3
Apogee Therapeutics
APGE
$10.1B
$154M 4.42%
2,323,456
– –
INSM icon
4
Insmed
INSM
$22.6B
$130M 3.72%
4,783,679
-566,321
-11% -$15.8M
DYN icon
5
Dyne Therapeutics
DYN
$4.1B
$129M 3.7%
4,555,383
+2,555,383
+128% +$57.8M
ALNY icon
6
Alnylam Pharmaceuticals
ALNY
$38.1B
$124M 3.56%
+832,310
New +$139M
GH icon
7
Guardant Health
GH
$18.9B
$124M 3.55%
6,000,000
+1,000,000
+20% +$21.4M
ARGX icon
8
argenx
ARGX
$54.9B
$118M 3.38%
300,000
– –
NTLA icon
9
Intellia Therapeutics
NTLA
$1.5B
$116M 3.32%
4,210,784
+1,960,784
+87% +$54.5M
OCUL icon
10
Ocular Therapeutix
OCUL
$1.83B
$116M 3.32%
12,721,460
+3,490,691
+38% +$24.8M
DVAX
11
DELISTED
Dynavax Technologies
DVAX
$113M 3.25%
9,141,660
+2,048,446
+29% +$26.7M
AXSM icon
12
Axsome Therapeutics
AXSM
$11.8B
$104M 2.98%
1,304,721
+304,721
+30% +$25.6M
ITCI
13
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$104M 2.97%
1,500,000
-500,000
-25% -$34.4M
GERN icon
14
Geron
GERN
$911M
$101M 2.88%
30,505,929
+922,480
+3% +$2.07M
AUTL
15
Autolus Therapeutics
AUTL
$378M
$97.4M 2.79%
15,272,172
+3,402,875
+29% +$21.2M
FDMT icon
16
4D Molecular Therapeutics
FDMT
$495M
$96.7M 2.77%
3,034,453
+750,081
+33% +$19.1M
ALKS icon
17
Alkermes
ALKS
$8.08B
$94.7M 2.71%
3,500,000
-500,000
-13% -$14.2M
BCYC
18
Bicycle Therapeutics
BCYC
$269M
$86.9M 2.49%
3,490,506
– –
PLRX icon
19
Pliant Therapeutics
PLRX
$65.6M
$85.7M 2.45%
5,750,000
– –
DFTX
20
Definium Therapeutics
DFTX
$5.56B
$62.7M 1.8%
+6,666,667
New +$38M
ABVX
21
Abivax
ABVX
$10.7B
$61.5M 1.76%
4,297,438
– –
VRDN icon
22
Viridian Therapeutics
VRDN
$2.14B
$60.5M 1.73%
3,456,053
-175,675
-5% -$3.41M
IONS icon
23
Ionis Pharmaceuticals
IONS
$9.04B
$59.5M 1.71%
1,373,475
+124,407
+10% +$5.93M
APLS
24
DELISTED
Apellis Pharmaceuticals
APLS
$58.8M 1.68%
+1,000,000
New +$63.7M
ANIP icon
25
ANI Pharmaceuticals
ANIP
$1.84B
$56.8M 1.63%
822,001
+222,001
+37% +$13.4M
1
2 3 4

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Deep Track Capital held 80 positions worth $3.49B, up 17% from $2.99B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Deep Track Capital deployed $299M of net new capital in Q1 2024, opening 20 new positions and adding to 14 existing holdings. Its largest new stake was Amgen: 550,000 shares worth $156M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier.

On the sell side, the largest reduction was AnaptysBio, an estimated $35.7M trimmed.

  • Deep Track Capital's largest Q1 2024 buy was Amgen: 550,000 shares worth $156M.
  • Deep Track Capital added most to Dyne Therapeutics in Q1 2024, an estimated $57.8M increase.
  • Deep Track Capital's biggest Q1 2024 reduction was AnaptysBio, cutting an estimated $35.7M.
  • Deep Track Capital fully exited Ambrx Biopharma Inc in Q1 2024, selling an estimated $52.8M.
  • Deep Track Capital's ten largest holdings make up 38% of its $3.49B portfolio in Q1 2024.
  • Deep Track Capital opened 20 new positions and closed 14 in Q1 2024.
  • Deep Track Capital's portfolio value rose 17% quarter-over-quarter to $3.49B.

Based on Deep Track Capital's 13F filing for Q1 2024, filed 15 May 2024.